In the present study, we investigated the effects of apolipoprotein A-I (apoA-I) on matrix metalloproteinase-2 (MMP-2) expression in vivo and in vitro. First, we detected the effects of apoA-I on aorta MMP-2, peroxisome proliferator-activated receptor a/g (PPAR a/g), cyclooxygenase-2 (COX-2), and nuclear factor kappa B (NF-kB) expressions in atherosclerotic rabbit models using immunohistochemical methods. The results showed that the expressions of MMP-2, COX-2, and NF-kB were decreased in aortas of atherosclerotic rabbits treated with apoA-I, while PPAR a/g expression was increased. Then, we chose the important inflammation cells, macrophages to testify those effects in vitro. Macrophages were divided into six groups and treated with different concentrations of apoA-I, the mRNA expressions of MMP-2, PPAR a/g, and COX-2 were then determined using reverse-transcription polymerase chain reaction, and protein expression of PPAR g, NF-kB were detected by western blot analysis. The levels of MMP-2 and PPAR a in cultured supernatants were determined using enzyme-linked immunosorbent assays. Interestingly, the in vitro results were similar to the results of the in vivo study. After incubation with apoA-I for 24 h, the expressions of MMP-2, COX-2, and NF-kB were decreased, while PPAR a/g expression was increased. In consideration of their particular roles in the process of making plaque stable in vivo and in vitro, we speculate that the inhibitory effect of apoA-I on MMP-2 expression may have a close relationship with the effects of apoA-I on PPAR a/g, COX-2, and NF-kB expressions. Although further research is needed to clarify the underlying mechanisms of these effects, our findings provide a novel insight into the anti-atherosclerotic plaque rupture effects of apoA-I.
Introduction
In the developed countries, coronary heart disease (CHD) has become the leading cause of death in the adult population. One contributing factor to CHD is the development of atherosclerosis, a condition associated with plaque formation, rupture, and subsequent thrombosis. It has been demonstrated that plaque rupture is related to the breakdown of the extra-cellular matrix (ECM) in the shoulder region of plaques [1, 2] . An inverse relationship between the risk of developing cardiovascular disease and the plasma concentration of high-density lipoproteins (HDL) has been identified in many studies [3] . Some studies in humans have shown that an increase in plasma HDL levels can slow the progression of atherosclerotic lesions and possibly stabilize unstable atherosclerotic plaques. Interestingly, in vitro HDL could block oxidized low-density lipoproteins (ox-LDL)-induced matrix metalloproteinase-2 (MMP-2) activation which can mediate plaque rupture and subsequent thrombosis, then promote formation of unstable plaque [4] . One of the important sources of MMP-2 is macrophages in atherosclerotic plaques [5] . MMP-2 expression determines the thickness of fibrous cap of the atherosclerotic plaque which has direct effects on the stability of atherosclerotic plaque and plaque rupture [6] . Therefore, we are attracted to probe into which component of HDL might make the most contribution to stabilization of plaque and inhibiton of MMP-2.
As the main structural and functional protein component of human HDL, apolipoprotein A-I (apoA-I) is known to have many anti-atherosclerotic properties [7, 8] . Importantly, many articles have indicated that there may be a relationship between apoA-I and plaque formation. Over-expression of human apoA-I can increase plaque smooth muscle cell content which leads to a more stable, less rupture-prone plaque in mice [9] . And plaque-stabilizing effects have been seen both in LDL-receptor-deficient mice treated with lipidated h-apoA-I and in uremic apoE2/2 mice treated with non-lipidated h-apoA-I [10, 11] . Moreover, Reimers et al. [12] have found that treatment with apoA-I have the potential to stabilize plaques and prevent plaque rupture in humans. Both apoA-I-containing compounds and apoA-I mimetic peptides have potential to be used clinically to promote atherosclerosis regression and stabilize existing plaques [13] . Our previous study in rabbits maintained on a high-fat diet showed that apoA-I could dramatically inhibit atherosclerosis and decrease the lesion area in aorta. In order to deeply explore the ability of apoA-I to prevent the plaque rupture, in this study we further investigated the effects of apoA-I on MMP-2 expression in atherosclerotic rabbits and in macrophages derived from THP-1 cells.
Besides, we also explored the effects of apoA-I on some relative molecules which may play key roles in the process of making plaque stable in vivo and in vitro. The expression of peroxisome proliferator-activated receptors (PPAR) a/g has been shown in atherosclerotic lesions and macrophagederived foam cells, and many studies indicate that PPAR a/g lead to a reduction of the risk for atherosclerosis [14] . PPAR a/g are members of the nuclear receptor super-family of ligand-binding transcription factors, and are associated to the tissue-specific expression of apoA-I [15] . PPRE and PPAR can directly regulate the transcription of some molecules, and it may negatively interfere with nuclear factor kappa B (NF-kB)-mediated signaling pathways.
NF-kB signaling pathway has received a growing attention in research of atherosclerosis, because it cannot only directly regulate molecules related to atherosclerosis such as MMP-2, but also affect other pathways participating in atherosclerosis [16] . The NF-kB/AP-1 family of transcription factors can regulate cyclooxygenase-2 (COX-2) gene expressions at the transcriptional level in macrophages [17, 18] . COX-2 is a major isoform of COX which induces many inflammation-related diseases, and its expression is limited to atherosclerotic lesions [19, 20] . Many studies have shown that COX-2 plays a key role in atherosclerosis [21] since the inhibition of COX-2 reduces early atherosclerotic lesion formation in murine models [22] . In addition, NF-kB, COX-2, and its products can affect the formation and stability of atherosclerotic plaques by regulating many important proteins involved in atherosclerosis, such as MMP-2 [23] .
It has been known that apoA-I can influence the process of atherosclerosis through regulating the expression of some inflammatory factors, such as intercellular adhesion molecule-1 and vascular cell adhesion molecule-1. However, studies concerning the effects of apoA-I on atherosclerotic plaques are limited. And the possible molecules related to the plaque stabilization of apoA-I have not been reported. Thus, we first investigated the effects of apoA-I on MMP-2 expression in vivo and in vitro. Moreover, the effects of apoA-I on other molecules associated to MMP-2 expression, such as PPAR a/g, NF-kB, and COX-2 were also explored in vivo and in vitro.
Materials and Methods

Chemicals and reagents
ApoA-I used in THP-1 cells was over-expressed in Pichia pastoris in our own laboratory. Roswell Park Memorial Institute (RPMI) 1640 medium, trypsin, and heatinactivated fetal bovine serum were obtained from Gibco (Carlsbad, USA). Phorbol 12-myristate 13-acetate (PMA) was purchased from Alexis Corporation (Lausen, Switzerland). 3--(4,5-dimethylthiazol-2-yl)-2-5-diphenyltetrazolium bromide (MTT) reagent was purchased from Sigma-Aldrich (St Louis, USA). Trizol reagent was purchased from Invitrogen (Carlsbad, USA).
Animal treatment
New Zealand white rabbits were provided by the Animal Research Center of Fudan University. To induce atherosclerosis, 20 male rabbits ( 2.0 kg body weight, 8 weeks old) were fed with a high-fat diet (98.5% standard diet with 1.5% cholesterol) for 8 weeks. Temperature and humidity were maintained at 24 + 28C and 55% + 15%, respectively. When the atherosclerosis was formed, rabbits were given standard chows and divided into two groups: group A contained 10 rabbits that were injected with pure h-apoA-I (30 mg/kg, once peer week), and group B contained 10 rabbits injected with physiological saline (5 ml, once peer week). ApoA-I used in rabbits was from human serum and provided by RAAS Blood Products Company (Shanghai, China). After 14 weeks, all the rabbits were sacrificed with an overdose of sodium pentobarbitone (140 mg/kg, intravenously). In each group, the aorta of rabbits were removed, fixed in situ with 10% buffered formaldehyde, and then embedded in paraffin. All procedures performed in this study were in accordance with institutional guidelines and followed the Chinese Physiological Society guidelines for animal research.
Immunohistochemistry staining
The aorta sections (4 mm) were deparaffinized in xylene and dehydrated in descending dilution of ethanol, followed by washing with phosphate-buffered saline (PBS) three times, 3 min for each time. Relevant reagents were purchased from Sinopharm Chemical Reagent Corporation (Beijing, China). For the antigen retrieval, sections were treated by microwave heating in citrate buffer ( pH 6.0) for 20 min and cooled naturally to room temperature. After wash with PBS, the endogenous peroxidase activity was blocked by incubating with 0.3% hydrogen peroxidase for 20 min at room temperature. After that, the sections were washed with PBS three times, and then were incubated ApoA-I inhibits MMP-2 expression in vitro and in vivo with 20% normal sheep serum for 30 min at room temperature, followed by MMP-2 (1 : 200), PPAR a/g (1 : 100), COX-2 (1 : 100), and NF-kB (1 : 50) primary antibodies (Santa Cruz Biotechnology, Santa cruz, USA) incubation for 2 h at 378C. The sections were washed with PBS three times 3 min for each time. The sections were incubated with EnVision reagent (DAKO Company, Copenhagen, Denmark) for 30 min at 378C. And then 3-3 0 -diaminobenzidin (Tiangen Biotech Company, Beijing, China) was used as the coloring agent and then incubated for 10 min. Finally, the sections were counterstained with Mayer's hematoxylin (Beyotime, Shanghai, China), and mounted with mounting medium (Beyotime).
Cell culture
The human monocytic cell line (THP-1) was purchased from Shanghai Institute of Biochemistry and Cell Biology, Chinese Academy of Sciences (Shanghai, China). To obtain the macrophages, THP-1 cells were cultured in serum-free RPMI 1640 (Gibco) medium containing PMA (Alexis Corporation) 100 ng/ml for 48 h until the cell density reached 1 Â 10 6 cells/ml. The macrophages derived from THP-1 cells were then divided into different groups and treated with different drugs according to the experimental design, respectively.
Cell viability assay
Cell viability was measured using the MTT assay. Macrophages derived from THP-1 cells were seeded at 1 Â 10 5 cells per well in 96-well plates. After being treated with apoA-I for 24 h, 20 ml of 5 mg/ml MTT (Sigma) solution was added to each well. After incubating for 4 h, the supernatant in each well was carefully removed, 200 ml of dimethyl sulfoxide was added to each well. The formazan crystals in each well were dissolved for 10 min, and the absorbance at 490 nm was measured on a microplate scanning spectrophotometer (DYNEX Technologies, Chantilly, USA).
Reverse-transcription polymerase chain reaction After being treated with apoA-I for 24 h, cells were harvested and used for extraction of total RNA. Total RNA was extracted using Trizol reagent (Invitrogen) according to the manufacturer's instruction. The total RNA (1 mg) was then converted to cDNA using reverse transcription kit (Thermo Fisher Scientific, Waltham, USA). Polymerase chain reaction (PCR) was performed using MMP-2, COX-2, and PPAR a/g specific primers which were synthesized by Sangon Gene Company (Shanghai, China) ( Table 1) . PCR cycling conditions were as follows: initial denaturation at 958C for 5 min, 30 cycles of denaturation at 958C for 45 s, annealing at 50-608C for 45 s, and elongation at 728C for 1 min, and one cycle of a final extension at 728C for 10 min. A portion (5 ml) of the PCR mixture was separated by electrophoresis in 1.2% agarose gel containing 1 mg/ml ethidium bromide. The gel bands were photographed and quantitatively measured by scanning densitometry using the Image Quant TL ECL and associated software (Image Quant TL, GE Healthcare, Piscataway, USA). The relative mRNA expression was normalized to the expression of GAPDH, and then compared with the control group.
Enzyme-linked immunosorbent assay THP-1 cells were seeded in six-well plates at a density of 5 Â 10 5 cells/well for 48 h in medium containing PMA. Then the macrophages were incubated with apoA-I for 24 h. MMP-2 and PPAR a levels in cultured supernatants were determined using enzyme-linked immunosorbent assay (ELISA) kits (RND Corporation, Minneapolis, USA). Cell suspension (50 ml) was added to each well of a 96-well plate. Standards were diluted to the indicated concentrations and added to 96-well plate in volume of 50 ml/ well. Fifty microliters of biotin was added to each well and incubated for 60 min at 378C. Then the plates were washed, and 60 ml of affinity streptomycin-horseradish peroxidase were added to each well and incubated for 30 min at 378C. 
ApoA-I inhibits MMP-2 expression in vitro and in vivo After wash, the 50 ml of substrate A and 50 ml of substrate B were added to each well and incubated for 10 min at 378C. Fifty microliters of stop solution was added to each well and the optical density (OD) was measured using a microplate scanning spectrophotometer (DYNEX Technologies, Chantilly, USA) at 450 nm.
Western blot analysis
The macrophage cells were pretreated with different drugs for 24 h. After treatment, the cells were washed twice with PBS and centrifugation at 1000 g for 5 min. The supernatant was discarded. The cells were suspended in RIPA lysis buffer, and placed on ice for 30 min, vibrated for several times. After centrifugation at 12,000 g for 5 min at 48C, the supernatant was collected. The protein concentration was determined using the Bio-Rad protein assay kit (Bio-Rad, Hercules, USA) with BSA as the standard. An aliquot of 60 mg protein from each sample was separated on 10% sodium dodecyl sulfate-polyacrylamide (SDS-PAGE) gel electrophoresis. The fractionated proteins were transferred to an immobilon polyvinylidene difluoride membrane (Amersham, Arlington Heights, USA). Then, the membrane was incubated with 5% skimmed milk in Tris-buffered saline solution with 0.1% Tween 20 (TBST) at room temperature for 1 h. Afterwards, the membranes were incubated with the primary antibody for PPAR g (1 : 1000, Cell Signaling, Danvers, USA) and NF-kB (1 : 200, BestBio Company, Shanghai, China) at 48C overnight, respectively, then with the secondary antibody (1 : 5000, Bioworld Technology, Minnesota, USA) at room temperature for 1 h. b-Actin (1 : 5000, Bioworld Technology) was used as a control for the protein loading. Immunoreactivity was detected by an enhanced chemiluminescent autoradiography (ECL kit, Tiangen Biotech Company) in accordance with the Chemilumilescent, Fluorescent and Visible Light Gel Imaging System (Fluorchem SP, Alpha Innotech, San Leandro, USA). The relative protein expression was normalized to the expression of b-actin, and then compared with the control group.
Statistical analysis
The data were expressed as mean + SEM of at least three or six experiments. Statistical analysis was performed by one-way analysis of variance for comparisons between two groups. Statistical significance was determined at P , 0.05. The statistical analysis was carried out using SSPS edition 16.0.
Results
Effects of apoA-I on expressions of MMP-2, PPAR a/g, COX-2, and NF-kB in aortas of atherosclerotic rabbits To investigate the effects of apoA-I on the expressions of MMP-2, PPAR a/g, COX-2, and NF-kB in aortas of atherosclerotic rabbits, the sections of injured aortas were stained with anti-MMP-2 antibody, anti-PPAR a antibody, anti-PPAR g antibody, anti-COX-2 antibody, and anti-NFkB antibody, respectively. In the experimental group, less staining for MMP-2 ( Fig. 1) was found as compared with the control group. Increased staining for PPAR a [ Fig. 2(A) ] and PPAR g [ Fig. 2(B) ] were found in the apoA-I-treated group when compared with the control group. In addition, Figure 1 Immunohistochemical analysis of MMP-2 level in aortas of atherosclerotic rabbits Color photomicrographs show representative immunostaining of cross sections from aortas with specific anti-MMP-2 antibody. Control group: atherosclerotic rabbits were injected with physiological saline (5 ml, once a week). Experimental group: atherosclerotic rabbits were injected with apoA-I (30 mg/kg, once a week). were found as compared with the control group. The results indicated that MMP-2, COX-2, and NF-kB expressions were decreased in aortas of atherosclerotic rabbits treated with apoA-I, while PPAR a/g expression was increased.
Effects of apoA-I on cell viability Cell viability was measured using the MTT reduction assay. After the cells were incubated with apoA-I at concentrations of 12.5, 25, 50, 100, and 200 mg/ml for 24 h, no toxic effect was observed (Fig. 3) . There was no significant difference when compared with the control (P . 0.05).
Effects of apoA-I on expression and release of MMP-2 in THP-1 macrophages After the macrophages were incubated with apoA-I at concentrations of 12.5, 25, 50, 100, and 200 mg/ml for 24 h, the expression of MMP-2 mRNA was decreased by 0.14%, 55%, 66.2%, 62.7%, and 27.3% [ Fig. 4(A,B) ], respectively. Accordingly, MMP-2 release from the cultured macrophages was also reduced by 32.2%, 34.2%, 62.3%, 60.5%, and 59.5%, respectively [ Fig. 4(C) ]. The results showed that the expression and release of MMP-2 were inhibited in THP-1 macrophages treated with apoA-I.
Effects of apoA-I on expression of PPAR a/g in THP-1 macrophages After the macrophages were incubated with apoA-I at concentrations of 12.5, 25, 50, 100, and 200 mg/ml for 24 h, the level of PPAR a mRNA in macrophages was increased by 24.8%, 30.9%, 47.8%, 26.8%, and 11.5% [ Fig. 5(A,B)] , and the protein level was increased by 54.5%, 77.8%, 126.2%, 80.8%, and 67%, respectively [ Fig. 5(C) ]. The level of PPAR g mRNA in macrophages was increased by 37.8%, 37.9%, 44.1%, 14.9%, and 13.4% [ Fig. 5(A,B)] , and the protein level was increased by 60%, 81.8%, 118.5%, 98.2%, and 68.4%, respectively [ Fig. 5(D) ]. The results indicated that expression of PPAR a/g were increased in THP-1 macrophages treated with apoA-I.
Effects of apoA-I on expression of NF-kB and COX-2 in THP-1 macrophages Additional studies were further carried out to determine the effects of apoA-I on NF-kB and COX-2 expression levels. Macrophages were incubated with apoA-I at a concentration of 12.5, 25, 50, 100, and 200 mg/ml for 24 h, NF-kB protein expression was significantly inhibited by 61.8%, 63.6%, 66.7%, 56.4%, and 52.6% [ Fig. 6(A,B) ] respectively, as compared with the control cells. In addition, COX-2 mRNA expression was decreased by 8%, 24.8%, 31.8%, and 9.7% at concentrations of 12.5, 25, 50, and 100 mg/ml [ Fig. 6(C,D) ]. The results showed that both NF-kB protein expression and COX-2 mRNA expression were inhibited in THP-1 macrophages treated with apoA-I.
Discussion
As the main structural and functional protein component of HDL, apoA-I plays a protective role against atherosclerosis. Figure 2 Immunohistochemical analysis of PPAR a/g, COX-2, and NF-kB levels in aortas of atherosclerotic rabbits Color photomicrographs show representative immunostaining of cross sections from aortas with specific anti-PPAR a antibody, anti-PPAR g antibody, anti-COX-2 antibody, and anti-NF-kB antibody. Control group: atherosclerotic rabbits were injected with physiological saline (5 ml, once a week). Experimental group: atherosclerotic rabbits were injected with apoA-I (30 mg/kg, once a week) (Â100). 
ApoA-I inhibits MMP-2 expression in vitro and in vivo
It has been known that making atherosclerotic plaque stable is an effective way to inhibit atherosclerosis. However, the effect of apoA-I on plaque stability is rarely studied, although a close relationship between apoA-I levels and plaques formation has been indicated in many studies. Therefore, we first investigated the effects of apoA-I on plaques by detecting the MMP-2 level which is closely related to atherosclerotic plaques in vivo and in vitro. The results showed that apoA-I significantly reduced the expression of MMP-2 in high-fat-treated rabbit thoracic aorta tissues and in macrophages derived from THP-1 cells.
In consideration of the important effects of MMP-2 on formation, structure, growth, and rupture of plaques, MMP-2 could significantly affect atherosclerosis process. Atherosclerosis is associated with plaque rupture and subsequent thrombosis. The atherosclerotic plaque is the complex lesion composed of distinct morphological features, including fibrous cap, shoulder area and lipid core. Rupture is associated with the breakdown of the ECM in the shoulder region of such plaques, and the risk of plaque rupture is influenced by specific characteristics of the plaque structure [24] . Indeed, the plaque with thin fibrous cap and large lipid core is more vulnerable to rupture. It has been postulated that thin cap fibroatheroma is the precursor lesion of plaque rupture [2] . MMP-2 was found to be highly expressed in macrophage-rich areas of atherosclerotic plaques, especially in thin cap plaques compared with plaques with the thick fibrous cap. MMP-2 determines the thickness of the fibrous cap of the atherosclerotic plaque and acts by degrading the ECM components within the plaque. So the existence of MMP-2 may aggravate the process of atherosclerosis. Fortunately, our present data showed that apoA-I can inhibit the MMP-2 expression both in atherosclerotic rabbits and in cultured macrophages, suggesting that apoA-I might alleviate rupture of atherosclerotic plaques via the inhibition of MMP-2.
To have a deeper understanding of inhibitory effect of apoA-I on MMP-2, we also determined some relative molecules possibly participating in this process, such as PPAR a/g, COX-2, and NF-kB in vivo and in vitro. Our study showed that PPAR a/g expression was enhanced, and NF-kB, COX-2 expressions were decreased in vivo and in vitro after being treated with apoA-I. The potential beneficial roles of PPAR a/g in atherosclerosis treatment and plaque stabilization have been supported by many studies [25, 26] . We speculate that the increase of PPAR a/g may be influenced by apoA-I through specific activity, but the accurate actions are still being explored in our laboratory. PPAR are expressed in atherosclerotic lesions and have been shown to affect gene transcription in macrophages. PPAR a/g can bind to specific DNA sequence elements (named as PPAR response elements) as heterodimers with retinoid X receptor, leading to gene expression [27] . It is reported that direct regulation of transcription via PPAR may negatively interfere with NF-kB-mediated transcription. ApoA-I inhibits MMP-2 expression in vitro and in vivo NF-kB signaling pathway regulates the inflammatory or developmental signals [28] . The mRNA expression and protein release of MMPs and other inflammatory cytokines can be regulated directly by NF-kB. Hence, we speculated that the inhibitory effects of apoA-I on MMP-2 mRNA expression and release may be affected by PPAR-NF-kB. Besides, COX-2 gene expression is also regulated by NF-kB at the transcriptional level in macrophages. The promoter of the COX-2 gene is known to contain two transcriptional regions, an enhancer and a basal promoter [29] . And the NF-kB binding site has been identified on the COX-2 promoters [30] . COX-2 can influence the structure and rupture of plaque through regulating the content of MMPs [21] . Our present results indicated that apoA-I can inhibit COX-2 and NF-kB expression in vivo and in vitro. Based on these results, we suggest that PPAR-NFkB-COX-2 might take part in the process of inhibiting the expression and release of MMP-2, which were induced by apoA-I. Moreover, it has been supported by increasing evidences that PPAR g can regulate COX-2 expression through a negative feedback loop [31] . So we think that PPAR g-COX-2 might also play key roles in the inhibitory effects of apoA-I on MMP-2 expression. And the present three possible processes might be partly overlapped and even be interrelated.
In conclusion, our study suggested that apoA-I exerts inhibitory effects on MMP-2 in vivo and in vitro. And after being treated with apoA-I, PPAR a/g expression was increased, while NF-kB and COX-2 expressions were inhibited in vivo and in vitro. These results indicated that apoA-I could stabilize plaque through suppressing MMP-2 expression, which contributing a lot to the treatment of atherosclerosis. We also found that PPAR a/g, NF-kB, and COX-2 might play important roles in the inhibitory MMP-2 expression effects of apoA-I. Although further research is needed to clarify the underlying mechanisms of these effects, our findings provide a novel insight into the antiatherosclerotic plaque rupture effects of apoA-I and suggest that apoA-I may be used for the treatment of atherosclerosis.
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